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Worldwide, in 2012, there were about 35.3 million people living with HIV/AIDS (PLWHA).1  Antiretroviral 
(ARV) significantly improved the livelihood of PLWHA through virological suppression, which has reduced HIV 
related mortality rates, and decreased the risk of HIV transmission through vaginal and anal sex.2,3 Optimal ARV 
adherence, around 95%, is required to maintain virological suppression.29 In 2000, a review paper reported that 
nonadherence rates were around 50-70%.30 Suboptimal adherence can lead to increased mortality, HIV 
transmission, and ARV resistance.2,3 Global suboptimal illustrates the importance of identifying barriers and 
facilitators to ARV adherence.7 Research is urgently needed to determine important barriers and facilitators that are 
specific to developing countries.3 It is crucial to consider the unique ways local factors shape how PLWHA 
experience and understand their ARV medications.  
The main objective of this qualitative study was to understand the ARV medication experiences of 
PLWHA in León, Nicaragua.  30 semi-structured, interviews were conducted in Spanish at the Hospital Escuela 
Oscar Danilo Rosales Arguello (HEODRA) Hospital in León, Nicaragua. A grounded theory approach was used to 
analyze interview transcripts. Religion emerged as a particularly salient aspect of the ARV medication experiences of 
HIV positive Nicaraguans. A close examination of the intersection of ARV and religious experiences may 
contribute to the understanding of major issues in PLWHA’s lives, which may contribute to ARV adherence. 
Interview data suggest that ARV medications were experienced in conflicting ways; namely as a source of life, and 
physical and social disruptions. Religion may reconcile this conflict by providing PLWHA with relief and resilience, 
which may reinforce their belief in ARVs’ life inducing qualities, in spite of physical and social disruptions. This 
mechanism may strengthen PLWHA’s commitment to their ARV medications, thus possibly facilitating ARV 








ARV Experiences are Geographically-Specific 
 
The literature indicates that ARV experience is geographically specific; therefore there is a need to 
understand how local social, cultural and economic context uniquely shape adherence. Studies have identified the 
following barriers to ARV adherence: being female, HIV stigma, fear of HIV disclosure, food insecurity, housing 
security, financial insecurity, substance abuse, mental health issues, decreased quality of life, work/family 
responsibilities, poor physician-patient relationships, forgetfulness, suspicion of treatment, complicated 
regimens, not understanding treatment benefits, number of pills required, being away from medication, 
falling asleep, medication side effects, access to medication, and long distance from home to treatment facility. 7-10-
19, 31, 32, 35 37, 38 
There is a gap in knowledge surrounding the ways local factors shape adherence in developing, 
resource-poor nations. In the 2006 systematic review, only 1 of 84 studies was conducted in a developed nation 
(Brazil in Latin America).31   This study cited financial constraints and access to medications as important barriers 
in developing nations.31  In addition, a recent literature search revealed adherence studies in Costa Rica and 
Peru.27,29 Both studies identified regimen characteristics or pill management as barriers.27,29 Studies also show that 
ARV facilitators in developed nations include having a sense of self-worth, seeing the positive effects of the ARV, 
acceptance of HIV status, understanding the importance of adherence, reminders, and the simplicity of the ARV 
regimen. 31 Research concerning facilitators in developing nations is less common. 31 
 
Religion and ARV Adherence 
Some studies have explored the ways that religion intersects with ARV medication experiences. For 
instance, data demonstrate that PLWHA perceive ARVs as having originated from God. Congolese PLWHA 
believed that “…God provided the knowledge to make ARVs…” Nigerian PLWHA viewed ARV medication 
effectiveness to be dependent on Allah’s dispositions.42 Islamic perspective dictates that Allah influences the 
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discovery, emergence, and provision of ARVs.43 Islamic faith also encourages PLWHA to seek treatment, since all 
“…servants of Allah must seek treatment for diseases.”43 
The intersection of religious and ARV experiences has several implications for ARV adherence. One study 
explored ARV adherence in Ugandan PLWHA through a sample that was predominately Christian (i.e. Christian 
80%, Muslim 20%, others 4%).  Researchers concluded that this sample was more likely to have increased ARV 
adherence if they had engaged in more religious behavior.44 Furthermore, those who self-reported as Pentecostal or 
Muslim had the highest percentage with high religiosity scores and ARV adherence. Similarly, a study of a 
predominantly Christian PLWHA in San Diego, CA found that higher annual household income and religious 
affiliation were predictive of higher adherence.45 Data from this study also revealed that PLWHA who viewed their 
beliefs as making their lives meaningful, creating a connection to a higher form, being important to recovery, and 
connecting them to humanity were more likely to be adherent. 45 Participants may remain adherent because they 
have maintained their personal autonomy, whilst successfully using God to cope with ARV medication challenges.45 
Religion may also intersect with ARV experiences in ways that may challenge adherence. For example, 
PLWHA from San Diego exhibited poorer adherence if they believed that God created everything, God will not 
turn his back on them, and displayed regular participation in religious rituals.45 (e.g. prayer, meditation). The 
religious ritual of particularly Ramadan complicates adherence, since Muslims must fast for a month, but ARVs 
must be taken with food. In these situations PLWHA must make a challenging choice: either listen to their religious 
ritual vs. adhere to treatment instructions.47  A similar theme emerged in the qualitative, semi-structured interviews 
of Malawian healthcare providers. Most providers attributed religion to their patients’ nonadherence because 
patients stopped taking their ARVs after being prayed at in church and during fasting (Muslims).46  Congolese 
PLWHA who believed their HIV was caused by witchcraft also interrupted their ARVs in favor of prayer and 
traditional mediations. Cultural traditions, such as spiritual healings, also caused 1.2% of a predominantly Christian, 
Ugandan PLWHA sample to discontinue their ARV medications.48   
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 Lastly, one study exploring PLWHA in Tanzania found that ARV adherence was mostly influenced by the 
participant’s education-level and knowledge of ARVs, as opposed to religious beliefs.49 In addition, data suggested 
that HIV stigma was strongly associated with religious beliefs (e.g. HIV is a punishment from or God, PLWHA 
have not followed the word of God). 
 
Local Context of ARV Experiences in Nicaragua 
There are several compelling reasons to study ARV adherence in Nicaragua. For instance, Nicaragua is a 
previously isolated nation, with a rapidly increasing HIV epidemic and strong stigmatization against PLWHA. 
Poverty and religion are highly salient in Nicaragua, thus having potential implications for adherence. Nonetheless, 
a literature review revealed there are no studies on ARV adherence in Nicaragua. 
During the 1980s, Nicaragua was isolated due to a ten-year civil war and an American economic blockade. 
In the 1990s, the end of the war was accompanied with a rapid increase in HIV transmission.5  This trend has 
continued; cases have increased from less than 500 to 1,500.1 This represents a 200% increase from 2001-2012. 
Higher estimates indicate the increase might be around 400%.1 In 2012, Nicaragua had a HIV prevalence rate of 
0.3%  (9,600 people).1  In Nicaragua HIV is mostly transmitted through sexual intercourse; 91% heterosexual 
transmission and 4% men who have sex with men (MSM).6  However, MSM transmission is unreported due to 
the stigmatizing social context.6,26 Studies indicate a high seroprevalence of 7.6% among MSM.25 
Reasons for increased HIV transmission include low condom use and increased migration after the war.4,5 
Seasonal migration is common among Nicaraguans who work in nearby countries. Migrant workers, who usually 
engage in casual/commercial sex, often experience limited healthcare access and stigma.5 As a result, they might be 
less likely to seek HIV testing or treatment.5 Stigma is such a pressing issue that the Nicaraguan Government 
enacted Nicaraguan Law 820, which promotes, protects, and defends the human rights of PLWHA. The objective 
of the law is to “…guarantee the respect, protection, and defense of the human rights of the people who are 





Nicaragua (GDP: 10,510 Millions of $US, in 201234) is one of the poorest Spanish speaking countries.5  
Despite of this, the Nicaraguan government has identified ARV treatment distribution as a national priority.5  
72% of Nicaraguan HIV patients are currently receiving ARV. 1  This has increased the survival of Nicaraguan 
PLWHA.5 Health-system barriers still contribute to incomplete ARV coverage. These include the delay in HIV 
status confirmation, the high cost (100 U.S. Dollars) of viral load and CD4 testing, and the delay in delivery 
of results to providers.5 
Finally, religion is very salient in Nicaragua. In 2005, data show that Nicaraguans identified with several 
religious denominations: Roman Catholic 58.5%, Protestant 23.3%, Jehovah’s Witnesses 0.9%, other 1.6%, and 




The main objective of this study was to understand how HIV-positive Nicaraguans experience their ARV 
medication regimens. This aim was addressed through an exploratory, qualitative approach. Semi-structured, in-
depth interviews were conducted to explore participants’’ general lifestyle, living with HIV, and their perceptions, 
attitudes, and behaviors towards ARV medication. 
 
Research Setting 
This study was conducted at the Hospital Escuela Oscar Danilo Rosales Arguello (HEODRA) Hospital in 
León, Nicaragua (population: 201,100 in 201236). HEODRA is a 400-bed, public hospital that is operated by the 
Nicaraguan Ministry of Health.52 HEODRA serves as the teaching hospital for the Universidad Nacional 
Autónoma de Nicaragua, León (UNAN-León). Participant recruitment and interviews were conducted at 
HEODRA’s Infectious Disease-HIV/AIDS Clinic. This clinic has a population of about 150 HIV+ patients and is 
staffed with infectious disease clinicians and a psychologist. The clinic also provides its HIV patients with ARVs, 
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which are provided by the Nicaraguan Ministry of Health and the World Fund. This study was conducted from 
July-August 2014. 
 
Sampling and Recruitment 
All eligible study participants were 18 years and older, HIV-positive, a patient of the HEODRA HIV 
Clinic, prescribed to ARV for at least three months, and had never participated in this study. All study participants 
gave informed consent and were able to communicate in Spanish, the official language of Nicaragua. 
30 participants were recruited and fully interviewed in Spanish. Previous studies have indicated that a 
sample size of about 5-25 participants is sufficient to achieve thematic saturation.32,33  A purposive sampling 
strategy was used to capture sufficient diversity in the qualitative sample. Diversity was considered in various 
ways, such as gender, age, sexual orientation, and ARV adherence profile.32  Nonadherent patients were defined 
as those with a history of treatment interruption or loss to clinic follow-up. 32 Please see table 1 for participant 
characteristics. 
Patients were mainly recruited from the HEODRA HIV clinic waiting room. Clinicians and support group 
leaders referred potential participants as well. Most participants were recruited from another ongoing portion of 
this study, which used quantitative surveys and chart reviews to collect information on the ARV adherence rate 
and the barriers and facilitators to adherence. Prospective participants were screened for study eligibility, including 
ARV treatment status, and briefed on study procedures during the consent process.  
 
Data Collection 
All interviews were conducted in a private room outside of the HEODRA HIV Clinic. Interviews followed 
the semi-structured Spanish interview guide from Curioso et. al.29, which was used to assess barriers and facilitators 
to ARV adherence in Lima, Peru. The interview questions were piloted with a group of local, Nicaragua medical 
students. Necessary changes were made, based on the students’ recommendations, to ensure cultural 
appropriateness. Clinical providers and researchers from the HEODRA Infectious Diseases Clinic and UNAN-
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León reviewed the updated guides. Interview guides were changed to inquire further about motivations to take ARV 
medication. 
The semi-structured interviews lasted a range of 15 minutes - 1 hour and 50 minutes. Patient interviews 
were audio recorded after consent was granted. The Principal Investigator, who is a Native Spanish speaker, 
conducted all interviews in Spanish. After participation, all participants received an eight-dollar supermarket gift 
card as a symbol of gratitude for their time. 
 
Data Analysis 
Spanish audio files were transcribed into Spanish by a third-party vendor. Transcripts were compared to 
the original recordings to ensure accuracy. A grounded theory approach was used to analyze interview transcripts 
and religion emerged as a salient theme. An iterative process was used to develop a codebook that was applied to all 
interview transcripts. Periodic research team meetings were held to discuss important codes and themes. The 
research team reviewed and redefined the initial codebook during these meetings. The finalized codebook contains 
codes that relate to pre-conceived and emergent themes. Transcripts were initially coded using the review feature on 
Microsoft Word. Finalized coding will occur using ATLAS.ti software. Spanish quotes that capture central themes 
were translated into English and every effort was made to preserve integrity.  
 
RESULTS 
Part II will focus on participants’ ARV medication experiences. Part II will explore how religion intersects 
with ARV medication experiences and its implications for ARV adherence. 
 
Part I: ARV Medication Experience 
ARVs are the “Elixir of Life” 
Data suggest that most participants viewed ARV medications as vital to ensuring their health and life. 
Participants showed their knowledge of ARV’s biological mechanisms (i.e. decrease viral load and increase CD4 
counts), which may shape the positive perception of their medication. This is demonstrated in the following quote 
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by Participant 1: …I have learned that it [ARV] helps us maintain—elevate our CD4 count, maintain the viral load 
undetectable, it [viral load] decreases constantly so the viral copies we have do not increase in number.” Several 
interviewees used personification to understand how ARVs control the HIV infection, as Participant 9 explains: ... 
the virus falls asleep, but, you feel normal…and that pill… if you do not take it, the virus runs. It goes and eats all 
the CD4 cells.” In some occasions, misunderstandings emerged regarding ARVs’ biological mechanisms (e.g. 
interchanging the meaning of CD4 and viral load) 
The belief that ARVs ensure life was able to influence ARV adherence in our participants. This favorable 
perception of ARVs was prevalent, including participants who did not understand ARV’s functions. Participant 7 
shares his view of ARVs: “I have to take my elixir of life, it’s true that I have to take it because I want to be well, I 
want to have a few more years of life, I want to achieve my dreams, my goals, I want to achieve them. In addition, 
Participant 3 spoke about how he reconciled painful side effects with his positive view of ARV, “I think that no, 
they [ARV] do not harm me, because what I think is that they are the best for me. And if I want to live more, I need 
to take them and not think that they will harm me. In the beginning, I felt very discouraged and weak. They [ARV] 
were very strong at first, but then you get used to them and they help a lot.” Eventually, ARV medications’ 
connotation of being instrumental to life encouraged participants to see the value of ARV adherence. This view is 
shown in the following recollection of Participant 4’s friend with AIDS: “The final stage is that one. She had her 
mouth full of blisters balls, her tongue—Oh, what horror! When I got to see her, I really wanted to cry. She only 
looked at me in the eyes, like she wanted to say” “Never, ever stop taking that medication. Look how I am now.” 
Participants also viewed ARV as important, since it provided the health and life necessary to ensure their 
families’ livelihood. This view encouraged ARV adherence, as demonstrated by Participant 8’s comment regarding 
what motivated his adherence: “…how long will I be alive to tend to my daughter, right? And having the necessary, 
daily job in order to sustain the family…my health, because without health, I can’t work, I can’t take care of my 
daughter”. Participant 6 expressed a similar motivator: “Oh, my children…to see them big, at least I could leave my 
oldest when he already has his career or at least at least he has his family apart from me. I know that if he is there, 
he will not leave the rest [of her children] alone”. PLWHA’s value of their family even encouraged Participant 19 to 
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re-adhere to ARVs: “Recently I abandoned them [ARVs] and today I will start to take them. I know that I can’t live 
without medication and I need to have a healthy life and provide my children with the best.” 
 
ARV Side Effects Contribute to Physical Disruptions for PLWHA 
 ARV medication experiences were greatly shaped by the severity of ARV medication side effects through 
physical disruptions of PLWHA’s daily lives. Physical disruptions were characterized by the debilitating physical 
ailments of ARV medications.  Participant 1 described examples of ARV side effects as “…they [those who take 
ARV] get insomnia, they get wet dreams, welts, issues with their body’s organism, gastritis…liver [issues]”. 
Participant 2 spoke about a particularly painful experience as follows, “[ARVs] were too strong, and no matter how 
often I would take it with my stomach full, it would always harm me. Then, I would feel myself starting to spit out 
blood, because my stomach was becoming more deteriorated each day, because of the [ARV brand name].” Physical 
disruptions manifested themselves in various forms, as explained by Participant 4: “Strong dizziness…You get up 
and it is like you are being carried away in the wind, and you have to hold on well, if not, then you fall. If you do not 
control it well, you fall. You have really bad dreams, because it’s [ARV] so heavy.”  
Physical disruptions contributed to important ramifications for participants’ ARV adherence.  The intensity 
of medication side effects complicated ARV adherence as demonstrated in the following quote by Participant 16: 
“When the side effects I felt were strong, I would say to myself “I am not going to take them”. Some of my 
colleagues would tell me, “You have to take it, that’s just a side effect, later on the side effect will go away”. Even 
previously adherent interviewees were not impervious to these damaging effects, as demonstrated by Participant 8: 
“After three days, I felt that I had to go to the bathroom to urinate more times… after two weeks…I became 
comfortable with the pills…[but]…15 days ago…I stopped taking them because it started for me—I felt disgust, 
the need to vomit, semi-headache. “Is it the pills?” I stopped taking them. I said to myself I will wait 20 days, and I 






ARV Medications Contribute to Social Disruptions for PLWHA 
Painful ARV side effects also contributed to social disruptions of PLWHA’s lives, thus impacting ARV 
adherence. For instance, some interviewees had to leave their employment due to worsened health from ARV side 
effects. Participant 6 spoke about her experience with ARV side effects at her workplace: “In my job yes, they knew 
my [HIV] status and they helped me with the most they could…when they saw that I would get sleepy, I did not 
feel well [they would say], “Go to the medical room and lay down or go to the bathroom and sit down for a 
moment.” I felt like a had a fever almost all the time.” Although Participant 6 was employed in a socially supportive 
workplace, the side effects proved too burdensome, as demonstrated by the quote “…the medication felt strong for 
me, then I felt my upset stomach, and instead of being well I felt that I had gotten sick. Then, it came to the point 
that I even had to leave my job because I no longer could”. Regardless of these disruptive challenges, Participant 6 
spoke about her attempt to be re-adherent: “I said to myself that today I will start taking it, and I will try to not 
leave it”. However, it can be difficult for PLWHA to become re-adherent when experiencing daily physical ailments. 
This challenge is demonstrated in Participant 10’s description of her work commute: “…when I would go out I 
would feel such anxiety in the bus or in the pickup truck-- to go home with dizziness, with anxiety in my heart, 
horrible—I suspended it [ARV] for some time because of the medication”.  
Participants’ ARV experiences revealed that HIV is a highly stigmatized condition in Nicaragua.  Several 
interviewees expressed this concern, as demonstrated in the following descriptions of HIV in Nicaragua: 
• Participant 6: “the worst part of HIV is not the disease, it’s the stigma…” 
• Participant 8: “it’s a discriminatory disease…” 
• Participant 15: “Even university students…How ignorant are they?...It’s in vain, I say. They are university 
students and they have given [HIV] trainings, I think to myself. And still, there they are, they are 
ignorant…of what AIDS is—HIV is not AIDS, Ok. The stage of AIDS is when we are, when we are at the 





• Participant 21:  
o “…because here in Nicaragua, to say HIV, you still cannot dare say—"t’s that I am an HIV 
carrier…” 
o “Because in Nicaragua, when someone is—when someone recognizes or someone knows—when 
they notice, then you are discriminated. It’s like—racism and Black people who do not have any 
rights to anything.” 
o “Then, we are pigs…we do not need to live, we will infect them [community]. But that’s due to 
the little information that they have…” 
 
This stigmatizing environment may have contributed to social disruptions, since ARV medications symbolized 
participants’ HIV positive status. As a result, several participants went through great lengths to hide details that 
could reveal the nature of their medications. For example, Participant 18 shared that her greatest ARV related 
challenge occured while she picked up her ARV medications. She explained that she “…I have to come and 
monitor everything because everyone knows my children—They might tell them something, so I only come. What I 
do is travel here, I make sure there is nobody and and I go inside quickly. She already knows me, so she gives it to 
me quickly, so I go upstairs to the pharmacy to pick it up.” Participant 13 described the process involved in bringing 
her ARV to the workplace: “…calculate the time I have to work, I calculate how long I will be at work and then I 
bring what [ARV dose] I need to take. When the time comes…I go and hide so nobody sees me…I say I hide 
because when I take the pill, that does not stop someone from asking, “Why are you taking those pills? Are you 
sick? Or “What do you have?” So, then, to avoid these questions, better that I do it hidden. I feel good like this.” 
Other participants were willing to take their ARV in public, but they concealed their reasons for taking their pills. 
Participant 17 explained: “…the guy I liked look at me various times and he tells me, “Why are you taking those 
pills?”, then the first times I told him, “Oh, it’s that I was sick with anemia”, I told him that.” 
Some PLWHA were unsuccessful at concealing the purpose of their ARV medications, thus indirectly 
revealing their HIV status. This scenario could potentially be incredibly stressful and socially disruptive for 
PLWHA. Nonetheless, Participant 5 mentioned an alternative occurrence with a lady he met while they sought 
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treatment for lung related complications. Participant 5 developed a friendship with her over a year and a half. 
Throughout this time he noticed that she was also taking ARV medications. He finally asked her about the 
medications and she replied: “They are mine…its for my lung issues”. “Oh, that’s fine”, I [Participant 5] told her. 
But after two or three days I kept insisting and I asked: “I know those pills.” Then, she says: “And why do you 
know them?” “Oh, it’s because my friend has showed me those pills before”, I told her. “And I know what they are 
for.” Then, she felt like—like bad inside, she must have said to herself: “He knows what I have.” Then, I said: 
“Don’t worry, I also take those pills.” Then she started to trust me more—she told me that…she had the 
disease…” This story shows how social support may counter the social disruptions that result from ARV 
medications, which symbolize a stigmatized condition.  
 
Part II: Intersection of Religious and ARV Experiences May Influence Experience 
Religion is a Source of Relief and Resilience for PLWHA 
Data suggest that religion is a source of relief and resilience that may help PLWHA overcome challenging 
situations. Participants received relief through God’s provision of essential needs for their life. For example, 
interviewees thanked God for granting employment security, food security, housing security, and health (i.e. 
emotional, mental, and physical wellbeing). Participants discussed how God ensured physical health through the 
stability of their HIV infection. For example, interviewees believed God ensured low viral loads, high CD4 counts, 
and the prevention and recovery from HIV-related opportunistic diseases. Participant 11 commented the following 
regarding her daughter’s defeat over her perinatal HIV infection: “I give thanks to God that my daughter, well, I 
look at her, she is healthy.” Participant 12 viewed God as a source of resilience while she contemplated the difficulty 
of disclosing her HIV status: “I did not tell him I was sick…after all those days…oh, beautiful God how can I tell 
him that I am sick, oh my God? If I tell him that I am sick, he will leave.” Participant 11 was asked to turn to 
religious faith and followers when her daughter was diagnosed with perinatally transmitted HIV. Her daughter’s 
doctor recommended that “…when you leave from here [medical center], take her to any church that you—the 




ARV Medications: One of God’s Tools to Ensure Life  
Intersection of religious and ARV experiences suggest that religion provides relief and resilience that may 
mediate conflicting ARV experiences. Relief and resilience may shape PLWHA’s belief in ARVs’ life inducing 
qualities, even while they endure undesired disruptions. For instance, several participants discussed how God 
“worked through” ARVs to ensure life. Participant 10 explains this idea: “…if He has sent me this medication 
because He also has made this medicine to alleviate all of the diseases we have gotten, but I am here because of 
Him.” On the contrary, several participants questioned the impact of ARVs, while they remained faithful to God. 
Participant 7 contemplated the role God and ARVs had in ensuring his child’s HIV negative status: “…my wife and 
I opted to have a kid, thanks to God my wife is of negative serology and my son came out negative, I don’t know at 
this point if it is a miracle or maybe the treatment does miracles, also it’s true I don’t know, I simply give thanks to 
God that my family is healthy…” In several challenging situations, participants lost their faith in ARVs, but 
remained committed to their belief in God’s ability to provide life. Participant 10 spoke about this situation in the 
following quote: “…I have resigned myself…the doctor told me that in the one year I have taken the medication, 
the virus has not decreased by much…I said to myself, this will not hurt me, I will overcome this and I don’t care 
what the doctor tells me…I have a God that can do it all and I know that He will take away all this virus…let’s 
think and have faith in God to keep moving forward.”  
 
God’s Influence Over Physical Disruptions  
 Interviewees suggested that God provided them with resilience to overcome distressing physical disruptions. 
For instance, interviewees were grateful God allowed them to overcome painful ARV side effects and successfully 
integrate their regimen into their daily lives. This idea is discussed by Participant 10: “…but I asked God, God give 
me the strength to overcome this [ARV side effects], but I felt desperately anxious every time I thought it was time 
to take the medication. I will have one year taking it [ARV medication] again…thanks to God it [ARV side effects] 
have all left...” God’s role in alleviating ARV side effects is discussed by Participant 19: “…my body will assimilate 
more [to the ARV] and will control it a little more because in the beginning one cannot control it because it’s very 
strong, but with the faith that I have in my Celestial Father, who is with me always, I know that will help me get 
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better.” For several subjects, like Participant 15, God’s role withstood the test of time: “…for me it has gone very 
well, because thanks to God, well, I have eight years and I have not relapsed…” 
 
Religion Influences Supportive Environments that May Alleviate Social Disruptions 
Religious faith and followers may address ARVs’ social disruptions by influencing the creation of socially 
supportive environments. Participant 20 explained this idea: “…thanks to God, my sons… they give me support 
and they say they have no problem, and that I have been a good mother to them, because I have been mother and 
father to them, I have worked to raise them, so they do not have a reason to discriminate me or anything.” –
Participant 1 discussed how religiously supportive environments may promote ARV adherence: “Thanks to God, 
the pastor who is there now—the [church] we are assisting, knows our condition and we have stayed there because 
of that, because they do not discriminate us, they support us. They don’t tell us to leave the treatment [ARV], or 
anything like that. On the contrary, they tell us to keep on going… When we started to have a congregation, where 
everyone accepted us and everything, we started to emotionally advance, and we felt better…we no longer have the 
idea that they [the community] will notice [our HIV status]”.  
 
Religious Faith and Followers May Contribute to Stigmatizing Environments  
Religion offered support that helped several participants manage challenging HIV and ARV medication 
experiences. However, some interviewees described the ways in which HIV stigma intersected with their religious 
beliefs. This intersection may complicate ARV adherence, since HIV stigma is a barrier to ARV adherence.8, 18 
Participants described the stigmatizing environment that was created by the religious followers through stories of 
their HIV status concealment, negative health behaviors (e.g. not seeking HIV care due to fear of rejection from 
religious congregation or the belief that God will ensure PLWHA’s children’s health), discrimination, and the spread 
of HIV misinformation. Participant 1 explained that his HIV status made him feel unwelcome in his religious 
community: “We were outside the church for four years because they discriminated us. The prior pastor was “in 
charge” of delivering bad information [about HIV] to the other pastors. This [pain] was worse for me spiritually, 
than the [issues] regarding my health”.  This quote exemplifies how HIV stigma can be more disruptive than HIV 
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health issues. Participant 23 described how her husband was unwelcomed: “There were many people, you know 
those who are religious, they say they are Christians, but they told me to abandon him [HIV positive husband]. 
Then, I, in my mind, I would think of so many [bad] things as a woman”.  
HIV stigma may also be explored through the belief that God that uses HIV as punishment. Participant 18 
discussed this theme in reference to her sister, a sex worker: “…she is in that world still…She comes in with a 
partner…God can punish her…” Participant 18 also thought that HIV is for “bad mothers” when she was first 
diagnosed with HIV: “I feel bad because I threw myself, I kneeled at the bottom of the desk, I cried bitterly, I 
clamored to God and told him, “Why did this [HIV infection] happen to me? I was not a bad mother to my 
children. I have never left them alone…I looked for food for them.” Religious communities also expressed that 
HIV was a punishment from God, as Participant 7 explained: “I used to go to a Christian church that I would 
spend the day at, relaxing, and passing by there was like a picnic, a camp—food, later they speak the word of 
God…talking about HIV was a punishment from God for the bad people, I would perceive that…” 
 
DISCUSSION 
 These findings demonstrate that religion interested with ARV medication experiences with potential 
implications for ARV adherence. Participants revealed they experienced ARV medications as a source of life and 
disruption. Religion furthered the idea that ARVs are a source of life, since some believed that ARVs were God’s 
tool for life. This is important, since the literature shows that the belief in ARV’s positive effects is a facilitator to 
adherence.31,38,40  Religion may also provide PLWHA with relief and resilience to manage challenging ARV 
medication and HIV experiences.45 For instance, God influenced the alleviation of ARV side effects, which is also a 
barrier to ARV adherence.31 In addition, religion influenced the creation of socially supportive environments, which 
is also a facilitator to ARV adherence.38,39,40 Nonetheless, in some scenarios, faith and followers created stigmatizing 
environments characterized by the exclusion and punishment of PLWHA. This practice has important 





Further research is needed on the role of religion in HIV care and ARV adherence.  This research should 
inform the creation of partnerships between religion and medical communities in Nicaragua. It is essential to 
develop programs between churches and clinics that capitalize on religion to create interventions that promote HIV 
health and ARV adherence. These programs should address religion’s ability to act as a barrier to adherence, while 
ensuring that positive religious aspects continue to encourage PLWHA’s health and life. Several participants 
specifically expressed their desire to see more programs and interventions that address HIV stigma through 
knowledge. Participant 19 expressed this idea: “...help us here in Nicaragua, maybe you [researchers abroad] will 
send us more information, so the people here, with help, will get rid of that fear that we will infect them with 
harm.” Future interventions should destigmatize HIV by providing knowledge of HIV transmission and 
emphasizing that everyone is at risk for HIV infection. In addition, these interviewees revealed the importance of 
emphasizing that God uses ARV adherence as a tool to promote health and life. As a result, every effort should be 
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APPENDICES   
 
Table 1. Demographic characteristics a-c  
Characteristic n=26 
Age (Years) 36.42 (22-56) 
Salary (monthly, $) 111.22 (0-444) 
Adherence rate (monthly, %) 76.21 (0-100) 
Sex  
   Female 10 (38.47) 
   Maled 16 (61.54) 
Sexual orientation  
   Heterosexual 18 (69.23) 
   Homosexual 4 (15.38) 
   Bisexual 4 (15.38) 
Education level  
  No school 2 (7.69) 
  Middle school (incomplete) 3 (11.54) 
  Middle school 3 (11.54) 
  High school (incomplete) 9 (34.62) 
  High school 3 (11.54) 
  University (incomplete) 3 (11.54) 
  University 3 (11.54) 
a Table values are mean (range) for continuous variables and n (%) for categorical variables.  
b Sample size represents data on 26/30 interviewees. 
c Percentages might not add up to 100% due to rounding. 
d Includes two male-female transgender participants. 
 
 
 
